Analysis of the rationality and safety of clinical application of anrotinib in a hospital

doi:10.19803/j.1672-8629.20230635

Abstract

Abstract: Objective To investigate the clinical application of anlotinib in a hospital and evaluate the rationality and safety of related medications, in order to standardize the clinical application of anlotinib. Methods To collect information on 106 patients with clinical application of amilorotinib in a county-level general hospital from January 1, 2022 to June 30, 2023, who received a total of 306 doses of amilorotinib-containing regimens, and to conduct a retrospective analysis of the reasonableness and safety of the clinical application of anlotinib. Results Among the 306 treatments, 89 cases (29.08%) of medication were irrational, and the types of irrationality were 47 cases (15.36%) of irrationality in combination of medication, 21 cases (6.86%) of over-indications, 19 cases (6.21%) of irrationality in dosage, and 2 cases (0.65%) of prohibited use of medication. There were 358 cases of adverse drug reactions (ADR) found in these medical records. The top five organ-system injury were diseases of the digestive system (30.73%), Metabolic and Nutritional Diseases (16.48%), diseases of the blood and lymphatic system (13.41%),diseases of the cardiovascular system (9.22%) and bleeding (5.31%). Conclusion Some irrationality in the clinical use of anrotinib in the hospital, the hospital and relevant quality control department should prescribe and rationally use anlotinib standardize the instructions of anlotinib, the latest domestic and international guidelines and consensus, strengthen the monitoring of medication, evaluate the adverse reactions, and improving the safety of anrotinib.

Key words: anlotinib, rationality, safety, adverse reactions, clinical pharmacist, medication monitoring

CLC Number:

R994.11

LIU Qi, ZHANG Yufeng, LUO Hao, LI Xin. Analysis of the rationality and safety of clinical application of anrotinib in a hospital[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 329-334.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230635

https://www.zgywjj.com/EN/Y2024/V21/I3/329

References

[1] SHEN GS, ZHENG FC, REN DF, et al.anlotinib: a novel multi- targeting tyrosine kinase inhibitor in clinical development[J]. Journal of Hematology & Oncology, 2018, 11(1): 120-131.
[2] JI YR, ZHANG WW, QU FF.Research progress on the anti-tumour mechanism of amlotinib[J]. Chinese Journal of New Drugs(中国新药杂志), 2023, 32(9): 906-910.
[3] National Health Commission of the People’s Republic China. Guidelines for the clinical application of new antineoplastic-drugs(2022)[EB/OL].(2022-12-29)[2022-12-30]. http://www.nhc.gov.cn/yzygj/s7659/202212/8df034c9afb44a9d95cd986d4e12fbd8.shtml.
[4] Guidelines Working Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Guidelines for the diagnosis and treatment of non-small cell lung cancer 2023(2023年CSCO 非小细胞肺癌诊疗指南)[M]. Beijing: People’s Health Publishing House, 2023.
[5] Chinese Society of Medical Oncology. Chinese Medical Association Journal.Chinese Medical Association Lung Cancer Clinical Guidelines(Version2023)[J]. Chinese Medical Journal(中华医学杂志), 2023, 103(27): 2037-2074.
[6] GE MH, GAO M, CHENG RC.Guidelines for integrated diagnosis and treatment of tumours in China.Thyroid Cancer(中国肿瘤整合诊治指南·甲状腺癌)[M]. Tian Jin:Tianjin Science and Technology Press(天津科学技术出版社), 2022: 1-138.
[7] National Cancer Institute. NCI Common Terminology Criteria for Adverse Events(CTCAE)Version5.0[EB/OL].(2017-11-27)[2018-04-19]. https://evs.nci.nih.gov/ftp1.
[8] GE MH, HUANG P, LU LQ, et al.Expert consensus on the use of amlotinib for over-indications[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2021, 38(24): 3102-3107.
[9] DU BP, ZHUANG LP, LIU S, et al.A survey of the use of amlotinib for over-indication in our hospitals[J].Pharmacy Today(今日药学), 2021, 31(3): 165-167, 171.
[10] ZHAO S, ZHANG M, ZHANG Q, et al.Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial[J]. BMC Cancer, 2024, 24(1): 6-17.
[11] QIAN JJ, XU R, DU Q, et al.An analysis of the rationality of drug provision in secondary specialised oncology hospitals[J]. Shanghai Pharma(上海医药), 2022, 43(9): 50-53, 62.
[12] LIU QY, HE F, SHEN L.Analysis of the use of antineoplastic drugs in 172 lung cancer patients in a hospital[J]. Journal of Dali University(大理大学学报), 2022, 7(10): 28-31.
[13] Guidelines Working Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Oesophageal Cancer Treatment Guidelines [中国临床肿瘤学会(CSCO)食管癌诊疗指南][M]. Beijing: People’s Health Publishing House(人民卫生出版社), 2021.
[14] CHENG Y, DU FC, FANG FQ, et al.Third-line treatment for metastatic colorectal cancer: Anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib[J]. Neoplasma, 2020, 67(6): 1384-1390.
[15] XIA NN, YANG JR, DAI J, et al. Effects and mechanism of action of amlotinib on proliferation and migration and invasion of cervical cancer cells[J].Journal of Tropical Medicine(热带医学杂志), 2023, 23(2):137-142, 148, 132.
[16] ZHANG L, JIANG JM, TAN TF, et al.A study of the correlation between plasma concentrations of anilotinib and adverse effects in patients with lung cancer[J].Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(18): 1876-1881.
[17] LI Z, CHEN H, SHI J, et al.A novel method for the quantification of anlotinib in human plasma using two-dimensional liquid chromatography[J]. Biomed Chromatogr, 2021, 35(12): e5218-e5227.
[18] SUN W, WANG Z, CHEN R, et al.Influencs of anlotinib on cytochrome P450 enzymes in rats using a cocktail method[J]. Biomed Res Int, 2017, 2017: 1-7.
[19] LIU QX, ZHU B, SONG YJ.Clinical value of carbamazepine concentration monitoring in antiepileptic therapy[J]. Journal of Clinical Drug Therapy(临床药物治疗杂志), 2010, 8(4): 20-23.
[20] HUANG W, ZHANG J, CHUA SS, et al.Induction of bil-irubin clearance by the constitutive androstane receptor (CAR)[J]. Proc Natl Acad Sci U S A, 2003, 100(7): 4156-4161.